This story was originally published on CFO.com. To receive daily news and insights, subscribe to our free daily CFO.com newsletter. Much ink has been spilled on the ever-expanding role of the CFO, but far less has been said about how such changes might affect the rest of the finance team. A recent survey by EY now aims to detail how the role of the corporate treasurer could change in the years ahead. The upshot? Treasurers, much like their CFO counterparts, are expecting a sea change in the near future. ...

Discover the path to becoming a Financial Risk Manager (FRM), including exam requirements, key responsibilities, and salary insights. Prepare for a career in risk management. https://t.co/9GF4zft2QY ...

山西华阳集团新能股份有限公司 关于阳泉煤业集团财务有限责任公司 的风险持续评估报告 根据《关于规范上市公司与企业集团财务公司业务往来的通知》 （证监 发〔2022〕48 号） ，《上海证券交易所上市公司自律监管指引第 5 号——交 易与关联交易（2023 年 1 月修订）》（上证发〔2023〕6 号）等文件要求， 上市公司应当每半年取得并审阅财务公司的财务报告，出具风险持续评估 报告，山西华阳集团新能股份有限公司（以下简称"本公司" ）通过查验阳 泉煤业集团财务有限责任公司（以下简称"财务公司" ）《金融许可证》 、《营 业执照》等证件资料，并审阅了财务公司 2025 年 6 月 30 日资产负债表和 营资质、业务和风险状况进行了评估，现将有关风险评估情况报告如下： 一、财务公司基本情况 财务公司是由华阳新材料科技集团有限公司（以下简称"华阳集团"） 、 立，接受国家金融监督管理总局监管的非银行金融机构。截至 2025 年 6 月 出 资 1,165,797,791.76 元 ， 占 注 册 资 本 的 65.51% ， 本 公 司 出 资 本公司及山西三维华邦集团有限公司共同收购原四通集团财务公司重组设 资 ...

Core Viewpoint - Shanxi Coking Coal Group Financial Co., Ltd. is a non-banking financial institution established by Shanxi Coking Coal Group Co., Ltd. and Shanxi Coking Energy Group Co., Ltd., with a registered capital of 3.55 billion RMB, and has undergone a comprehensive risk assessment [1][9]. Group 1: Company Overview - The financial company was established on December 15, 2009, and is located in Taiyuan, Shanxi Province [1]. - The company is jointly funded by Shanxi Coking Coal Group (80% stake) and Shanxi Coking Energy Group (20% stake) [1]. - The financial company has a registered capital of 3.55 billion RMB [1]. Group 2: Organizational Structure - The highest authority of the financial company is the shareholders' meeting, which is supported by a board of directors and a supervisory board [2]. - The board of directors includes several committees: Risk Management Committee, Compensation and Assessment Committee, and Audit Committee [3]. Group 3: Business Scope - The financial company engages in various financial services, including accepting deposits, providing loans, bill discounting, and financial consulting for member units [4]. Group 4: Internal Control - The financial company has established a comprehensive internal control system, including governance structures and internal control measures to ensure effective risk management [4][5]. - The company emphasizes a culture of risk management and regularly conducts internal training to enhance employee skills [4]. Group 5: Financial Performance - As of June 30, 2025, the financial company reported total assets of approximately 45.65 billion RMB and total liabilities of approximately 39.92 billion RMB, with a liquidity ratio of 45.97% and a capital adequacy ratio of 16.97% [7]. - The company achieved an operating income of approximately 572.96 million RMB and a net profit of approximately 283.87 million RMB in the first half of 2025 [7]. Group 6: Risk Management - The financial company has maintained a good risk management status, with no significant risk events reported since its establishment [8]. - The company has established a comprehensive risk management framework to control various types of risks, including credit and liquidity risks [8]. Group 7: Regulatory Compliance - The financial company meets all regulatory requirements as per the "Enterprise Group Financial Company Management Measures" [9]. - The company has not encountered any major issues that could affect its normal operations or financial stability [8][10].

Group 1 - The article discusses the expertise of Sean Daly in ETFs, biotech, and FINTECH solutions within the banking sector, highlighting his academic background and extensive writing on various economic topics [1] - Sean Daly has a global strategy and private equity background, focusing on long/short and event-driven equity approaches, particularly in small-cap biotech and emerging markets [1] Group 2 - There are no disclosures related to stock positions or business relationships with companies mentioned in the article [2] - The article emphasizes that past performance does not guarantee future results and does not provide specific investment recommendations [3]

Group 1 - RH (NYSE: RH) stock has significantly underperformed compared to the S&P 500 index since the end of 2021, making it a challenging holding for investors who bought in during that year [1] - The company has faced difficulties in maintaining its stock value, indicating potential issues in its business model or market positioning [1] Group 2 - The article does not provide specific financial metrics or performance data for RH, focusing instead on the general sentiment surrounding the stock's performance [1]